<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115762</url>
  </required_header>
  <id_info>
    <org_study_id>ASK-LC-B1202-1</org_study_id>
    <nct_id>NCT03115762</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics,Safety and Immunogenicity of ASKB1202 in Chinese Healthy Subjects: a Randomized, Double-blinded, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Aosaikang Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will investigate the pharmacokinetic,immunogenicity and safety biosimilarity of
      ASKB1202 compared to bevacizumab sold in China and Europe.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Maximum measured concentration of the analyte in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Time to peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 100 days</time_frame>
    <description>Terminal-phase elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ASKB1202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of ASKB1202</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bevacizumab B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells</description>
    <arm_group_label>bevacizumab A</arm_group_label>
    <arm_group_label>bevacizumab B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASKB1202</intervention_name>
    <arm_group_label>ASKB1202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Healthy males,aged 18 to 50 years. 2.A complete medical history, including disease
             history,physical examination, vital signs, 12-lead electrocardiogram (ECG), and chest
             X-ray image.

             3.Clinical laboratory tests is normal or the abnormality is not clinical significant
             determined by researchers.

             4.The subjects were willing to take effective contraceptive measures within 2 months
             before use of the drug and 6 months after.

             5.The subjects could understand the procedures and methods of this study, were willing
             to strictly abide the clinical trial plan to complete the test, sign the Informed
             Notice.

        Exclusion Criteria:

          -  1.Any evidence of a historical or existing clinically relevant concomitant disease, as
             determined by researchers.

             2.Acute,chronic active infections during screening of the study and admission(1 day
             before treatment),or has a history of active tuberculosis.

             3.Hemorrhaged or donated blood (including the components of blood donation)， or
             received blood transfusion ≥400 mL within 3 months before screening；Hemorrhaged or
             donated blood (including the components of blood donation) ≥200 mL within a month
             before the screening .

             4.Any finding of abnormality which has clinical significance during the screening of
             the clinical tests determined by researchers.

             5.Currently suffering from hypertension,abnormal blood pressure during study screening
             and hospital admission(1 day before use of drug):systolic blood pressure &gt; 140 mmHg
             and/or diastolic blood pressure &gt; 90 mmHg.

             6.Any disease causes it to increase the risk of bleeding or thrombosis, such as
             bleeding or thrombosis genetic predisposition, or has a history of traumatic
             hemorrhage, thromboembolic events, blood coagulation disease and thrombocytopenia
             (platelet count &lt;100000/L) or international standardization ratio (INR) is higher than
             1.44.

             7.Suffered or suffering from clinical significant atopic allergy, hypersensitivity or
             allergic reaction, including known or suspected sensitive to one component in drug;
             abnormal serum immunoglobulin E (IgE) determined by researchers.

             8.Abnormal electrocardiogram (ECG) with clinical significance, such as QTc interphase
             is greater than 450 milliseconds.

             9.A history of gastrointestinal perforation or any fistula. 10.Has a wound without
             healing or fracture in study screening and admission. 11.Orthostatic hypotension,
             syncope and dizziness or has a history of shock caused by any reason.

             12.Suffered from malignant tumors (except that controlled basal cell carcinoma and
             squamous cell carcinoma).

             13.Has been vaccinated within 4 weeks before screening , or plan to get the vaccine
             during the study period.

             14.Has a history of taking beacizumab or anti VEGF targeted agents or having the
             antibody of anti VEGF.

             15.Participated in another trial within three months prior to administration or had a
             monoclonal antibody therapy within twelve months prior to administration.

             16.Received a surgery within 28 days prior to administration, including dental suture
             or wound dehiscence, or plan to undergo surgery including dental surgery during the
             study and 60 days after the last administration of the protocol specified treatment.

             17.Used any drug that is harmful to major organs within 3 months before
             administration,or use any drug within 14 days prior to participation.

             18.Smoker who smoked ＞5 cigarettes per day within 3 months prior to the research and
             unable to refrain from smoking during the research.

             19.History of alcohol abuse(drink alcohol more than 14 units a week [1 unit = 285 mL
             beer or 25 mL of liquor or 100 mL of wine); positive result for alcohol breath test
             within 24h before treatment;or unable to refrain from drinking during the study.

             20.History of taking drugs or drug abuse;or positived result for drug screening;or
             unable to refrain from drug abuse during the study.

             21.Positive hepatitis b surface antigen , hepatitis c antibody , HIV antibody and
             syphilis antibody.

             22.Any condition that not suitable to anticipate the research or bring obvious risks
             to the subjects according to researchers.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASKB1202</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

